MAPT and amyloidosis: Plasma p-tau217 can distinguish between individuals with autopsy-confirmed AD and cognitively unimpaired individuals with better accuracy than alternative plasma and MRI-based measures of AD pathology [21], and has been shown to reflect both amyloid and tau pathologies [14].